Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma - PubMed (original) (raw)
Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma
Michael I Koukourakis et al. Neoplasia. 2005 Jan.
Abstract
Pyruvate dehydrogenase (PDH) catalyzes the conversion of pyruvate to acetyl-coenzyme A, which enters into the Krebs cycle, providing adenosine triphosphate (ATP) to the cell. PDH activity is under the control of pyruvate dehydrogenase kinases (PDKs). Under hypoxic conditions, conversion of pyruvate to lactate occurs, a reaction catalyzed by lactate dehydrogenase 5 (LDH5). In cancer cells, however pyruvate is transformed to lactate occurs, regardless of the presence of oxygen (aerobic glycolysis/Warburg effect). Although, hypoxic intratumoral conditions account for HIF1alpha stabilization and induction of anaerobic metabolism, recent data suggest that high pyruvate concentrations also result in HIF1alpha stabilization independently of hypoxia. In the present immunohistochemical study, we provide evidence that the PDH/PDK pathway is repressed in 73% of non small cell lung carcinomas, which may be a key reason for HIF1alpha stabilization and "aerobic glycolysis." However, about half of PDH-HIF pathway, and patients harboring these tumors have an excellent postoperative outcome. A small subgroup of clinically aggressive tumors maintains a coherent PDH and HIF/LDH5 expression. In contrast to cancer cells, fibroblasts in the tumor supporting stroma exhibit an intense PDH but reduced PDK1 expression favoring maximum PDH activity. This means that stroma may use lactic acid produced by tumor cells, preventing the creation of an intolerable intratumoral acidic environment at the same time.
Figures
Figure 1
Expression patterns of PDH and PDK in normal lung and lung cancer. (a) Strong cytoplasmic expression of PDH in normal bronchi (thick arrows) and adjacent stroma fibroblasts (thin arrows). (b) Intense PDH expression in the alveolar tissue (thick arrows). (c) Lack of PDH expression in a squamous cell lung carcinoma (thin arrows) adjacent to PDH-positive alveolar tissue (thick arrows). (d) Focal PDH expression in cancer cells (black arrows). (e) Lack of PDH expression in squamous cell lung cancer (thin arrows) in a background of tumor-supporting stroma exhibiting a strong PDH reactivity (thick arrows). Strong expression of PDK in cancer cells (thin arrows) of a squamous cell carcinoma (f) and adenocarcinoma (g). Note the repression of PDK in the tumor-supporting stroma (thick arrows).
Figure 2
Kaplan-Meier overall survival curves according to PDH expression, stratified for HIF1α (a) and LDH5 expression (b) (n = 42). Note that cases with contemporaneous defective metabolism in both aerobic (low PDH expression) and anaerobic (low HIF1α or low LDH5) directions had a particularly favorable outcome.
Similar articles
- Metabolic Connection of Inflammatory Pain: Pivotal Role of a Pyruvate Dehydrogenase Kinase-Pyruvate Dehydrogenase-Lactic Acid Axis.
Jha MK, Song GJ, Lee MG, Jeoung NH, Go Y, Harris RA, Park DH, Kook H, Lee IK, Suk K. Jha MK, et al. J Neurosci. 2015 Oct 21;35(42):14353-69. doi: 10.1523/JNEUROSCI.1910-15.2015. J Neurosci. 2015. PMID: 26490872 Free PMC article. - HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia.
Kim JW, Tchernyshyov I, Semenza GL, Dang CV. Kim JW, et al. Cell Metab. 2006 Mar;3(3):177-85. doi: 10.1016/j.cmet.2006.02.002. Cell Metab. 2006. PMID: 16517405 - Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis.
Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC, Harris AL; Tumour and Angiogenesis Research Group. Koukourakis MI, et al. Br J Cancer. 2003 Sep 1;89(5):877-85. doi: 10.1038/sj.bjc.6601205. Br J Cancer. 2003. PMID: 12942121 Free PMC article. - Enzymes involved in l-lactate metabolism in humans.
Adeva M, González-Lucán M, Seco M, Donapetry C. Adeva M, et al. Mitochondrion. 2013 Nov;13(6):615-29. doi: 10.1016/j.mito.2013.08.011. Epub 2013 Sep 9. Mitochondrion. 2013. PMID: 24029012 Review. - Metabolic reprogramming by the pyruvate dehydrogenase kinase-lactic acid axis: Linking metabolism and diverse neuropathophysiologies.
Jha MK, Lee IK, Suk K. Jha MK, et al. Neurosci Biobehav Rev. 2016 Sep;68:1-19. doi: 10.1016/j.neubiorev.2016.05.006. Epub 2016 May 11. Neurosci Biobehav Rev. 2016. PMID: 27179453 Review.
Cited by
- Novel Dichloroacetophenone-Based PDHK1 Inhibitors as Potent Anticancer Agents.
Wu P, Zhang Z, Zhou Y, Liu Q, Tam KY, Su Z. Wu P, et al. Drug Des Devel Ther. 2024 Oct 18;18:4661-4679. doi: 10.2147/DDDT.S473437. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 39440140 Free PMC article. - Molecular characterization of Gleason patterns 3 and 4 prostate cancer using reverse Warburg effect-associated genes.
Georgescu I, Gooding RJ, Doiron RC, Day A, Selvarajah S, Davidson C, Berman DM, Park PC. Georgescu I, et al. Cancer Metab. 2016 May 5;4:8. doi: 10.1186/s40170-016-0149-5. eCollection 2016. Cancer Metab. 2016. PMID: 27152194 Free PMC article. - Therapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1.
James MO, Jahn SC, Zhong G, Smeltz MG, Hu Z, Stacpoole PW. James MO, et al. Pharmacol Ther. 2017 Feb;170:166-180. doi: 10.1016/j.pharmthera.2016.10.018. Epub 2016 Oct 19. Pharmacol Ther. 2017. PMID: 27771434 Free PMC article. Review. - Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia.
Murat A, Migliavacca E, Hussain SF, Heimberger AB, Desbaillets I, Hamou MF, Rüegg C, Stupp R, Delorenzi M, Hegi ME. Murat A, et al. PLoS One. 2009 Jun 17;4(6):e5947. doi: 10.1371/journal.pone.0005947. PLoS One. 2009. PMID: 19536297 Free PMC article. - Inhibition of pyruvate dehydrogenase kinase‑1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming.
Xu H, He Y, Ma J, Zhao Y, Liu Y, Sun L, Su J. Xu H, et al. Int J Oncol. 2020 Sep;57(3):733-742. doi: 10.3892/ijo.2020.5098. Epub 2020 Jul 10. Int J Oncol. 2020. PMID: 32705170 Free PMC article.
References
- Harris RA, Bowker-Kinley MM, Hyang B, Wu P. Regulation of the activity of the pyruvate dehydrogenase complex. Adv Enzyme Regul. 2002;42:2249–2259. - PubMed
- Reed LJ, Hackert ML. Structure-function relationships in dihydrolipoamide acyltransferases. J Biol Chem. 1990;265:8971–8974. - PubMed
- Sanderson SJ, Miller C, Lindsay JG. Stoichiometry, organisation and catalytic function of protein X of the pyruvate dehydrogenase complex from bovine heart. Eur J Biochem. 1996;236:68–77. - PubMed
- Maeng CY, Yazdi MA, Niu XD, Lee HY, Reed LJ. Expression, purification, and characterization of the dihydrolipoamide dehydrogenase-binding protein of the pyruvate dehydrogenase complex from Saccharomyces cerevisiae. Biochemistry. 1994;33:13801–13807. - PubMed
- Harris RA, Bowker-Kinley MM, Wu P, Jeng J, Popov KM. Dihydrolipoamide dehydrogenase-binding protein of the human pyruvate dehydrogenase complex. DNA-derived amino acid sequence, expression, and reconstitution of the pyruvate dehydrogenase complex. J Biol Chem. 1997;272:19746–19751. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous